Menu Back to Feature-Sessions

New Feature Sessions for 2018!

Elevate Your Experience through Interactive Sessions

Joining DIA means joining conversations and driving change in the industry. DIA Europe 2018 opens up even more opportunities for dialogue within the programme sessions.

New DIAlogue Sessions:

Dynamic, outcome-focused sessions where stakeholders converge to solve a real problem.


  • DIA Europe 2018 Value Access IconThe Role of Unmet Need in Regulatory and Pricing Decision Making

    18 April, 10:30 - 12:0

    Moderator: Jens Grueger, Head of Global Pricing and Market Access, F. Hoffmann-La Roche, Switzerland
    In this dialogue session, we will explore two areas in detail:
    1. A high unmet medical need usually gets easier reimbursement. Can stakeholders agree on a definition of high unmet need that would provide more predictability for all?
    2. Should there be a different assessment of price relative to value in drugs that address areas of high unmet need?

  • DIA Europe 2018 Translational Medicine IconThe New EMA First-in-Human (FIH) Guideline. Part 1: Non-Clinical Aspects

    17 April, 14:00 - 15:30

    Session Co-Chairs:

    • Salah-Dine Chibout, Global Head of Discovery and Investigative Safety (DIS) and Global Head Therapeutic Areas in Preclinical Safety, Novartis, Switzerland; Chair of InnoMeds, EFPIA
    • Jan Willem van der Laan, Senior Assessor Pharmacology- Toxicology, MEB and EMA Chair of Safety Working Party, Netherlands
    During this session we will engage in a dialogue with the different stakeholders (e.g. regulators, industry, academics etc.) on the non-clinical aspects of the the revised “Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products”.
  • DIA Europe 2018 Translational Medicine IconThe New EMA First-in-Human (FIH) Guideline. Part 2: Clinical Aspects

    18 April, 10:30 - 12:00

    Session Co-Chairs:

    • Salah-Dine Chibout, Global Head of Discovery and Investigative Safety (DIS) and Global Head Therapeutic Areas in Preclinical Safety, Novartis, Switzerland; Chair of InnoMeds, EFPIA
    • Jan Willem van der Laan, Senior Assessor Pharmacology- Toxicology, MEB and EMA Chair of Safety Working Party, Netherlands
    This session is a continuation of the session “New EMA FIH guideline: Non-clinical aspects”. During this session we will to engage in a dialogue with the different stakeholders (e.g. regulators, industry, academics etc.) on the clinical aspects of the guideline.